Patient-Derived 3D Tumor Model Efficacy Evaluation Services
Most oncology candidates that clear preclinical screening still fail in the clinic. For immuno-oncology programs the failure often traces back to biology the model never contained, including stromal barriers, immunosuppressive signaling, and the immune compartment itself. ProNAMs reconstructed tumor microenvironment models bring these components into the assay, so that mechanism, resistance, and immune engagement can be interrogated before your candidate reaches a clinical decision point.
From Tumor-Only 3D Culture to a Reconstructed Tumor Microenvironment
Conventional patient-derived 3D tumor culture expands tumor cells alone in animal-derived basement membrane matrices, which limits its readouts to tumor-intrinsic drug sensitivity. Our reconstructed TME models combine tumor cells with immune cells, cancer-associated fibroblasts (CAFs), and endothelial cells. Animal-derived matrices are replaced with defined synthetic hydrogels and decellularized extracellular matrix (dECM), and the culture format is selected per endpoint from static, air-liquid interface (ALI), or dynamic perfusion. Perfusion configurations support preliminary microvascular networks. Together these components allow T-cell infiltration, cytotoxicity, and immune evasion to be measured directly within the assay.
| Conventional Tumor-Only 3D Culture | ProNAMs Reconstructed TME Model | |
|---|---|---|
| Concept | 3D expansion of tumor cells | Comprehensive reconstruction of the TME |
| Cellular Composition | Almost exclusively tumor cells | Tumor cells + Immune cells + CAFs + Endothelial cells |
| Culture Matrix | Animal-derived basement membrane extract | Defined synthetic hydrogels and decellularized ECM (dECM) |
| Culture Format | Static submerged culture | Static, air-liquid interface (ALI), or dynamic perfusion, selected by endpoint |
| Vascularization | None | Perfusable microvascular networks (available on MPS-based configurations) |
| Immune System | Cannot simulate immune responses | Evaluates T-cell infiltration, cytotoxicity, and immune evasion |
| Throughput | High-throughput; ideal for basic chemo/targeted screening | Medium-throughput; ideal for deep mechanistic and immuno-oncology validation |
| Applications | Chemo/Targeted drug sensitivity, genetic mutation analysis | Immuno-oncology, TME-targeted drugs, Anti-angiogenic therapies |
Why a Reconstructed Tumor Microenvironment?
Physiological tumors are dynamic ecosystems rather than isolated cell clusters. Moving from monoculture to a reconstructed TME brings three classes of biology into the assay.
Physical and paracrine communication between tumor cells, CAFs, and immune cells is restored, allowing stroma-mediated resistance to emerge in the assay rather than in the clinic.
Native antigen presentation, T-cell activation and exhaustion trajectories, and checkpoint pathways including PD-1/PD-L1 are retained within an autologous context.
Defined matrices with tunable stiffness support ECM remodeling, invasion, and the mechanical contribution to drug resistance - processes that static animal-derived matrices obscure.
Next-Generation Technologies for TME Reconstruction
ALI 3D Barrier Models
Air-liquid interface culture of intact tumor fragments preserves endogenous tumor-infiltrating lymphocytes (TILs) and stromal cells native to the patient's TME, providing a direct model for immunotherapy evaluation without cellular dissociation.
Advanced Co-Culture Systems
Optimized formulations sustain co-culture of purified tumor microtissues with autologous or allogeneic PBMCs, CAFs, and endothelial cells, maintaining viability across lineages with differing metabolic requirements.
Microphysiological Systems (MPS) and Dynamic Perfusion
Perfusion platforms apply regulated fluid shear stress to support microvascular network formation, enabling real-time visualization of immune cell rolling, extravasation from engineered vessels, and infiltration into the solid tumor core.
Next-Gen Biomaterials and 3D Bioprinting
Defined synthetic hydrogels and dECM reduce the lot-to-lot variability inherent to animal-derived matrices. The third-party bioprinting is applied to control spatial architecture, matrix stiffness, and biochemical gradients.
Patient-Derived Model Panels
Our platform leverages a clinically annotated model repository with documented consent and provenance, spanning high-incidence and difficult-to-treat cancer types, each optimized for immediate co-culture and efficacy evaluation.
| Cancer Type | Subtype / Clinical Characteristics | Key Mutations | Biomarker Annotation |
|---|---|---|---|
| Breast | TNBC, HR+/HER2-, HER2+ | BRCA1/2, PIK3CA | ER, PR, HER2 |
| Colorectal | Primary and hepatic metastasis | KRAS, BRAF V600E | MSI-H/dMMR vs MSS |
| Pancreatic | Highly desmoplastic, chemo-resistant | KRAS, TP53, SMAD4, CDKN2A | Stromal density scoring |
| Ovarian | High-grade serous, Platinum-resistant | BRCA1/2, TP53 | HRD status |
| Melanoma | Advanced / metastatic | BRAF V600, NRAS | PD-L1 expression |
Key Applications of Our Services
Our services are designed to address the complex challenges in the development of modern cancer therapies.
Immuno-Oncology Drug Evaluation
- Immune Checkpoint Inhibitors: Evaluate anti-PD-1/PD-L1 candidates for T-cell reactivation in autologous immune-competent models, with MSI-H/dMMR versus MSS stratification available in colorectal panels.
- Cell Therapies: Utilize dynamic perfusion MPS to evaluate CAR-T cell trafficking, penetration of the physical TME barrier, and solid tumor cytotoxicity.
- Bispecific Antibodies: Measure T-cell–tumor cell bridging efficiency within a 3D spatial environment.
TME-Targeted Drug Discovery
- Stroma-Directed Agents: Perform focused evaluation of CAF-inhibitory candidates and anti-angiogenic compounds in vascularized perfusion configurations.
Mechanistic and Translational Studies
- Resistance and Invasion Biology: Observe matrix degradation, tumor invasion, migration, and immune evasion mechanisms driven by TME-secreted immunosuppressive factors.
Study Design and Deliverables
| Parameter | Specification |
|---|---|
| Sample Input | Fresh surgical resection or core biopsy; minimum viable tissue mass confirmed at intake |
| Model Establishment | Success rate and expansion timeline reported per case prior to assay initiation |
| Assay Turnaround | Confirmed at study design; dependent on model availability and endpoint panel |
| Quality Control | Viability, morphology, and marker-expression QC at each passage; inter-replicate CV reported with every dataset |
| Readouts | Flow cytometry, live-cell and confocal imaging, cytokine profiling, spatial transcriptomics |
| Data Package | Raw data, processed datasets, QC records, and an interpreted study report |
Why Partner with ProNAMs?
As a specialized NAMs service provider, ProNAMs is dedicated to delivering robust, reproducible, and translationally relevant data that moves your pipeline forward.
Accelerate Your Translational Pipeline
Access ethically compliant, clinically annotated patient-derived model panels optimized for complex co-culture assays and predictive evaluation. Speak with our scientific experts to design a bespoke evaluation protocol tailored to your molecule's unique mechanism of action.
Schedule a Consultation